DB:HXXB

Stock Analysis Report

Executive Summary

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States.


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Idera Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HXXB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-3.9%

HXXB

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

-40.6%

HXXB

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: HXXB underperformed the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: HXXB underperformed the German Market which returned 6.1% over the past year.


Shareholder returns

HXXBIndustryMarket
7 Day-3.9%-4.1%-5.7%
30 Day-12.4%-8.2%-5.7%
90 Day-7.5%-2.0%-3.6%
1 Year-40.6%-40.6%4.0%3.7%9.3%6.1%
3 Year-89.2%-89.2%38.2%36.7%8.9%-0.7%
5 Year-95.4%-95.4%9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is Idera Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Idera Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

1.24x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HXXB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HXXB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HXXB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: HXXB is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HXXB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HXXB is good value based on its PB Ratio (1.2x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Idera Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

40.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HXXB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HXXB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HXXB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HXXB's revenue (66.1% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: HXXB's revenue (66.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HXXB is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Idera Pharmaceuticals performed over the past 5 years?

-6.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HXXB is currently unprofitable.

Growing Profit Margin: HXXB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HXXB is unprofitable, and losses have increased over the past 5 years at a rate of -6.8% per year.

Accelerating Growth: Unable to compare HXXB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HXXB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: HXXB has a negative Return on Equity (-120.75%), as it is currently unprofitable.


Next Steps

Financial Health

How is Idera Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: HXXB's short term assets ($45.1M) exceed its short term liabilities ($7.8M).

Long Term Liabilities: HXXB has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: HXXB is debt free.

Reducing Debt: HXXB has no debt compared to 5 years ago when its debt to equity ratio was 1.6%.


Balance Sheet

Inventory Level: HXXB has a low level of unsold assets or inventory.

Debt Coverage by Assets: HXXB's debt is not covered by short term assets (assets are -1287.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HXXB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: HXXB has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of -12.9% each year.


Next Steps

Dividend

What is Idera Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HXXB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HXXB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HXXB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HXXB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HXXB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Vinnie, Vin Milano (55yo)

5.2yrs

Tenure

US$1,781,944

Compensation

Mr. Vincent J. Milano, also known as Vinnie and Vin, serves as Director at Aclaris Therapeutics, Inc. since January 7, 2020. He has been the Chief Executive Officer and President at Idera Pharmaceuticals,  ...


CEO Compensation Analysis

Compensation vs Market: Vinnie, Vin's total compensation ($USD1.78M) is above average for companies of similar size in the German market ($USD415.76K).

Compensation vs Earnings: Vinnie, Vin's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Vincent Milano
President5.2yrsUS$1.78m0.21% $91.2k
John Kirby
Senior VP & CFO1.3yrsUS$553.87k0.030% $13.0k
Robert Fletcher
Senior Vice President of Business Development & Strategic Planning5.1yrsUS$977.45k0.010% $4.3k
Joanna Horobin
0.6yrsUS$993.93k0.0086% $3.7k
Louis Arcudi
1.3yrsUS$986.13k0.022% $9.5k
Robert Doody
Senior Vice President of IR & Corporate Communications5.2yrsno datano data
Bryant Lim
Senior VP1.4yrsno data0.027% $11.4k
Jill Conwell
Senior Vice President of Human Resources5yrsno datano data
Elizabeth Tarka
Senior VP & Chief Medical Officer0.6yrsno datano data
Shah Rahimian
Medical Director & Global Clinical Lead for Oncology0yrsno datano data

1.4yrs

Average Tenure

55.5yo

Average Age

Experienced Management: HXXB's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Vincent Milano
President5.2yrsUS$1.78m0.21% $91.2k
Michael Dougherty
Director0.8yrsno data0.039% $16.6k
James Geraghty
Chairman6.6yrsUS$153.48k0.23% $97.4k
Howard Pien
Independent Director1.4yrsUS$142.14k0.080% $34.5k
Maxine Gowen
Independent Director4.1yrsUS$100.99k0.0030% $1.3k
Cristina Csimma
Director0.8yrsno datano data
Mark Goldberg
Independent Director6.1yrsUS$100.46k0.035% $14.9k
Carol Schafer
Independent Director1.2yrsUS$51.86k0.071% $30.4k

2.8yrs

Average Tenure

61yo

Average Age

Experienced Board: HXXB's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HXXB insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.


Top Shareholders

Company Information

Idera Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Idera Pharmaceuticals, Inc.
  • Ticker: HXXB
  • Exchange: DB
  • Founded: 1989
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$46.773m
  • Listing Market Cap: US$42.993m
  • Shares outstanding: 28.87m
  • Website: https://www.iderapharma.com

Number of Employees


Location

  • Idera Pharmaceuticals, Inc.
  • 505 Eagleview Boulevard
  • Suite 212
  • Exton
  • Pennsylvania
  • 19341
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IDRANasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 1996
HXXBDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1996

Biography

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer. The company was founded in 1989 and is based in Exton, Pennsylvania. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 21:35
End of Day Share Price2020/02/25 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.